“Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns: Original scientific article”, ADMET DMPK, p. 2956, Oct. 2025, doi: 10.5599/admet.2956.